GCP
LENZ

GSA Capital Partners’s LENZ Therapeutics LENZ Stock Holding History

GSA Capital Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,455
Closed -$263K – 2232
2025
Q4 		$263K Buy
16,455
+4,613
+39% +$134K 0.02% 1243
2025
Q3 		$552K Buy
+11,842
New +$435K 0.05% 776
2025
Q1 		– Sell
-8,385
Closed -$242K – 2145
2024
Q4 		$242K Sell
8,385
-1,972
-19% -$60.1K 0.02% 1327
2024
Q3 		$246K Buy
+10,357
New +$230K 0.02% 1327
2023
Q2 		– Sell
-5,726
Closed -$98K – 2006
2023
Q1 		$98K Sell
5,726
-24,916
-81% -$403K 0.01% 1363
2022
Q4 		$712K Buy
30,642
+3,399
+12% +$78.8K 0.09% 393
2022
Q3 		$605K Buy
27,243
+12,621
+86% +$301K 0.08% 439
2022
Q2 		$281K Buy
+14,622
New +$326K 0.04% 866

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

GSA Capital Partners's LENZ Position: Q1 2026 in Review

GSA Capital Partners sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 16,455 shares — an estimated $263K sold.

GSA Capital Partners first reported a position in LENZ in Q2 2022 and held it in 8 quarters. The position peaked at $712K in Q4 2022. 146 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • GSA Capital Partners reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 16,455 LENZ Therapeutics shares in Q1 2026, an estimated $263K.
  • GSA Capital Partners first reported a position in LENZ Therapeutics in Q2 2022 and held it in 8 quarters.
  • GSA Capital Partners's LENZ Therapeutics position peaked at $712K in Q4 2022.
  • 146 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.